Comparing two HIV treatments for people with TB
Part of Infections clinical trials.
This study tests a new combo pill for HIV (ainuovirine, lamivudine, and tenofovir) against a standard pill (efavirenz, lamivudine, and tenofovir) in people who have both HIV and tuberculosis. It aims to find a treatment that works well and has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You weigh at least 40 kg (about 88 pounds) and your body mass index (BMI) is between 18.5 and 30.
- You have never taken HIV medications before (treatment-naive).
- You have active tuberculosis (TB) and are taking TB drugs that include rifampicin and isoniazid.
- Your CD4 count is at least 25 cells/µL and your viral load is under 500,000 copies/mL.
- You do not have TB meningitis, drug-resistant TB, or severe liver or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-drug HIV treatment for people who are new to HIV therapy and also have tuberculosis. It compares the two-drug combination to the standard three-drug regimen, with the goal of making treatment simpler while still being effective.
This study tests if a two-drug HIV regimen (darunavir/cobicistat plus lamivudine) works as well as a standard three-drug regimen in men whose HIV is already well-controlled. If effective, this could mean taking fewer medications.
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
This study tests a new combination of two drugs to see if they can reduce the 'hidden' HIV that stays in your body even when you're on regular HIV treatment. The goal is to work toward a cure, not just control.
This trial tests if a two-drug HIV regimen (darunavir/cobicistat plus lamivudine) works as well as a three-drug regimen (darunavir/cobicistat plus tenofovir alafenamide/emtricitabine) in men whose HIV is already suppressed. The goal is to find a simpler, effective option that may have fewer side effects.
This trial compares a two-drug regimen of doravirine and lamivudine to another two-drug regimen of dolutegravir and lamivudine for people with HIV who have had a suppressed viral load for at least 24 months. The goal is to see if the newer combination works as well as the current one.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.